{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:58:20Z","timestamp":1784231900782,"version":"3.55.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Cytomegalovirus (CMV) infection poses a significant risk to immunosuppressed transplant recipients, manifesting through primary infection, reinfection, or reactivation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We analyzed the emergence of drug resistance in CMV infection in 3 patients who were later found to have received an allograft from a shared, deceased donor. The seronegative transplant recipients developed symptomatic CMV infections after bowel\/pancreas, kidney, or lung transplantation. Prospective Sanger sequencing was used to identify mutations in the viral DNA polymerase (DP) and protein kinase (PK). DP and PK variants were retrospectively quantified by targeted next-generation sequencing. The impact of the novel DP-A505G substitution on drug susceptibility was assessed using a recombinant virus. Whole-genome sequencing of clinical CMV samples was enabled through target DNA enrichment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>The DP-A505G substitution was found in all patient samples and could be associated with a natural polymorphism. A subsequent review of the patients\u2019 clinical histories revealed that they had all received organs from a single donor. The CMV infection exhibited divergent evolution among the patients: patient 1 developed resistance to ganciclovir and foscarnet because of 2 DP mutations (V715M and V781I), patient 2 showed no genotypic resistance, and patient 3 developed ganciclovir (PK-L595S) and maribavir resistance (PK-T409M). Interpatient variation across the entire CMV genome was minimal, with viral samples clustering in phylogenetic analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>All 3 transplant recipients were infected with the same donor-derived CMV strain and readily developed different drug susceptibility profiles. This underscores the importance of judicious antiviral drug use and surveillance in preventing antiviral resistance emergence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000005209","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:30Z","timestamp":1727654430000},"page":"890-899","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Dynamics and Evolution of Donor-derived Cytomegalovirus Infection in 3 Solid Organ Transplant Recipients With the Same Multiorgan Donor"],"prefix":"10.1097","volume":"109","author":[{"given":"Fien","family":"Horsten","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunwen","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Veterans Affairs Medical Center, Research Service, Portland, OR."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gillemot","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Debaveye","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Naesens","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation Research Group, KU Leuven, Leuven, Belgium."},{"name":"Department of Nephrology and Kidney Transplantation, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Pirenne","sequence":"additional","affiliation":[{"name":"Abdominal Transplant Surgery Unit, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium."},{"name":"Department of Abdominal Transplant Surgery and Transplant Coordination, University Hospitals Leuven, Leuven, Belgium."},{"name":"Leuven Intestinal Failure and Transplantation Center (LIFT), University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanhoutte","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Nephrology and Kidney Transplantation Research Group, KU Leuven, Leuven, Belgium."},{"name":"Department of Nephrology and Kidney Transplantation, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Vanuytsel","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (ChroMetA), KU Leuven, Leuven, Belgium."},{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases and Metabolism (ChroMetA), KU Leuven, Leuven, Belgium."},{"name":"Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Maes","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Rega Institute, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"R1-20250714","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R2-20250714","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients.","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics"},{"key":"R3-20250714","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients.","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"R4-20250714","doi-asserted-by":"crossref","first-page":"10332","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus management in solid organ transplant recipients: a pre-COVID-19 survey from the Working Group of the European Society for Organ Transplantation.","volume":"35","author":"Grossi","year":"2022","journal-title":"Transplant Int"},{"key":"R5-20250714","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40121-022-00746-1","article-title":"New insights on CMV management in solid organ transplant patients: prevention, treatment, and management of resistant\/refractory disease.","volume":"12","author":"Kotton","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R6-20250714","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus.","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R7-20250714","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/342844","article-title":"Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients.","volume":"186","author":"Lurain","year":"2002","journal-title":"J Infect Dis"},{"key":"R8-20250714","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.","volume":"14","author":"Boivin","year":"2009","journal-title":"Antivir Ther"},{"key":"R9-20250714","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.","volume":"65","author":"Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R10-20250714","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/tid.12507","article-title":"Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.","volume":"18","author":"Timpone","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R11-20250714","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/tid.12537","article-title":"Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.","volume":"18","author":"Young","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R12-20250714","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection.","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"R13-20250714","doi-asserted-by":"crossref","first-page":"e13521","DOI":"10.1111\/tid.13521","article-title":"Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.","volume":"23","author":"Mehta Steinke","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"R14-20250714","doi-asserted-by":"crossref","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.","volume":"176","author":"Chou","year":"2020","journal-title":"Antiviral Res"},{"key":"R15-20250714","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance.","volume":"163","author":"Piret","year":"2019","journal-title":"Antiviral Res"},{"key":"R16-20250714","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial.","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R17-20250714","doi-asserted-by":"crossref","first-page":"11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection.","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int"},{"key":"R18-20250714","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection.","volume":"226","author":"Chou","year":"2022","journal-title":"J Infect Dis"},{"key":"R19-20250714","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/AAC.01177-08","article-title":"Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.","volume":"53","author":"Chou","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20250714","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chom.2011.01.006","article-title":"Antiviral inhibition targeting the HCMV Kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest.","volume":"9","author":"Reitsma","year":"2011","journal-title":"Cell Host Microbe"},{"key":"R21-20250714","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients.","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R22-20250714","doi-asserted-by":"crossref","first-page":"vew014","DOI":"10.1093\/ve\/vew014","article-title":"Antiviral drug resistance as an adaptive process.","volume":"2","author":"Irwin","year":"2016","journal-title":"Virus Evol"},{"key":"R23-20250714","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/infdis\/jix157","article-title":"Characterization of human cytomegalovirus genome diversity in immunocompromised hosts by whole-genome sequencing directly from clinical specimens.","volume":"215","author":"Hage","year":"2017","journal-title":"J Infect Dis"},{"key":"R24-20250714","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jmv.20127","article-title":"Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection.","volume":"73","author":"Alain","year":"2004","journal-title":"J Med Virol"},{"key":"R25-20250714","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jviromet.2015.04.022","article-title":"Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants.","volume":"221","author":"Thys","year":"2015","journal-title":"J Virol Methods"},{"key":"R26-20250714","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcv.2016.04.017","article-title":"Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients.","volume":"80","author":"Garrigue","year":"2016","journal-title":"J Clin Virol"},{"key":"R27-20250714","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.antiviral.2019.06.004","article-title":"Persistent primary cytomegalovirus infection in a kidney transplant recipient: multi-drug resistant and compartmentalized infection leading to graft loss.","volume":"168","author":"Andrei","year":"2019","journal-title":"Antiviral Res"},{"key":"R28-20250714","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1128\/AAC.49.7.2710-2715.2005","article-title":"Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.","volume":"49","author":"Chou","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20250714","article-title":"Utilization of Agilent SureSelect target enrichment for whole genome sequencing of viruses and bacteria.","author":"Williams"},{"key":"R30-20250714","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/molbev\/msu300","article-title":"IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies.","volume":"32","author":"Nguyen","year":"2015","journal-title":"Mol Biol Evol"},{"key":"R31-20250714","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nmeth.4285","article-title":"ModelFinder: fast model selection for accurate phylogenetic estimates.","volume":"14","author":"Kalyaanamoorthy","year":"2017","journal-title":"Nat Methods"},{"key":"R32-20250714","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jit654","article-title":"Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.","volume":"209","author":"Chou","year":"2014","journal-title":"J Infect Dis"},{"key":"R33-20250714","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2016.12.003","article-title":"Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.","volume":"138","author":"Chou","year":"2017","journal-title":"Antiviral Res"},{"key":"R34-20250714","doi-asserted-by":"crossref","first-page":"e00922","DOI":"10.1128\/AAC.00922-18","article-title":"New locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir.","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"Pt 12","key":"R35-20250714","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1099\/0022-1317-77-12-3099","article-title":"Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors.","volume":"77","author":"Mendelson","year":"1996","journal-title":"J Gen Virol"},{"issue":"Pt 7","key":"R36-20250714","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1099\/vir.0.81891-0","article-title":"Latency and reactivation of human cytomegalovirus.","volume":"87","author":"Sinclair","year":"2006","journal-title":"J Gen Virol"},{"key":"R37-20250714","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-virology-110615-042422","article-title":"Human cytomegalovirus latency: approaching the Gordian knot.","volume":"3","author":"Goodrum","year":"2016","journal-title":"Annu Rev Virol"},{"key":"R38-20250714","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.TP.0000165430.65645.4F","article-title":"Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations.","volume":"80","author":"Zamora","year":"2005","journal-title":"Transplantation"},{"key":"R39-20250714","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12594","article-title":"Cytomegalovirus infection in solid organ transplant recipients.","volume":"20","author":"Lumbreras","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R40-20250714","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/infdis\/jiaa450","article-title":"Donor cytomegalovirus transmission patterns in solid organ transplant recipients with primary infection.","volume":"223","author":"Hasing","year":"2021","journal-title":"J Infect Dis"},{"key":"R41-20250714","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/infdis\/jiz208","article-title":"Human cytomegalovirus genomes sequenced directly from clinical material: variation, multiple-strain infection, recombination, and gene loss.","volume":"220","author":"Su\u00e1rez","year":"2019","journal-title":"J Infect Dis"},{"key":"R42-20250714","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1128\/AAC.48.5.1865-1868.2004","article-title":"Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I.","volume":"48","author":"Fillet","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-20250714","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11262-018-1627-3","article-title":"Human cytomegalovirus genomics and transcriptomics through the lens of next-generation sequencing: revision and future challenges.","volume":"55","author":"Mart\u00ed-Carreras","year":"2019","journal-title":"Virus Genes"},{"key":"R44-20250714","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3389\/fmicb.2016.01317","article-title":"Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus.","volume":"7","author":"Houldcroft","year":"2016","journal-title":"Front Microbiol"},{"key":"R45-20250714","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/v13030399","article-title":"Detection of genotype-specific antibody responses to glycoproteins B and H in primary and non-primary human cytomegalovirus infections by peptide-based ELISA.","volume":"13","author":"Zavaglio","year":"2021","journal-title":"Viruses"},{"key":"R46-20250714","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fcimb.2020.00267","article-title":"Whole-genome approach to assessing human cytomegalovirus dynamics in transplant patients undergoing antiviral therapy.","volume":"10","author":"Su\u00e1rez","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"R47-20250714","doi-asserted-by":"crossref","first-page":"e0082923","DOI":"10.1128\/jcm.00829-23","article-title":"Development and validation of a next-generation sequencing assay with open-access analysis software for detecting resistance-associated mutations in CMV.","volume":"61","author":"Mallory","year":"2023","journal-title":"J Clin Microbiol"},{"key":"R48-20250714","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13073-020-00791-w","article-title":"Best practices for variant calling in clinical sequencing.","volume":"12","author":"Koboldt","year":"2020","journal-title":"Genome Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T20:00:39Z","timestamp":1752523239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005209","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}